New pill TQB3122 enters first human tests for advanced cancers

NCT ID NCT07269145

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 20 times

Summary

This early-stage study tests a new oral drug, TQB3122, in about 86 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors or slow disease. Participants will take capsules and be closely monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100050, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Meizhou People's Hospital (Meizhou Academy of Medical Sciences)

    NOT_YET_RECRUITING

    Meizhou, Guangdong, 514031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Tenth People's Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200072, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sichuan Cancer Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.